Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance
Filings
42 filings of TORNTPHARM since January 2025; the newest 40 below.
board outcome 12, transcript 8, presentation 7, credit rating 6, dividend 5, results 2
| Filed | Type | Subject | |
|---|---|---|---|
| 29 Oct 2026 | transcript | Torrent Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryTorrent Pharmaceuticals filed a letter dated 29 October 2026 under Regulation 30(6) of the SEBI LODR Regulations, 2015. The letter states that the transcript of the conference call with analysts and investors on the financial results for the quarter and half year ended 30 September 2026 has been placed on the company's website. The pages provided do not include the transcript itself, so management's remarks and their tone cannot be summarised from this filing. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Oct 2026 | board outcome Acquisition, Legal, Results | Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryTorrent Pharmaceuticals' board approved the audited standalone and unaudited consolidated financial results for the quarter and half year ended 30 September 2026 at a meeting held on 23 October 2026. The standalone results include the financials of erstwhile J. B. Chemicals & Pharmaceuticals Limited (JBCPL), merged under a scheme of amalgamation approved by the NCLT on 6 July 2026 with an appointed date of 21 January 2026. The statutory auditor, BSR & Co. LLP, issued an unmodified audit opinion on the standalone results. The auditor's report notes that FY2026 comparatives include JBCPL results for 21 January 2026 to 31 March 2026, with total revenue of Rs. 712.74 crores and net profit after tax of Rs. 133.97 crores. The company also enclosed a press release on the financial results. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Oct 2026 | credit rating Rating | Torrent Pharmaceuticals Limited has informed the Exchange about Credit RatingAI summaryTorrent Pharmaceuticals intimated under Regulation 30 of SEBI LODR that India Ratings and Research Private Limited affirmed the credit rating and revised the outlook from stable to positive for the Company's existing banking facilities, issuer rating and Non-Convertible Debentures, with rating IND AA+/Positive. India Ratings also affirmed the rating of the existing commercial paper and assigned a rating to the proposed commercial paper, both at IND A1+. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Sep 2026 | acquisition Acquisition, Capex | Torrent Pharmaceuticals Limited has informed the Exchange about Acquisition - Disclosure pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations )AI summaryTorrent Pharmaceuticals filed an amendment to its Share Subscription and Shareholders' Agreement dated 28 September 2026 for Torrent Urja 27 Private Limited, raising its investment from INR 7,91,93,400 to INR 11,87,90,100 due to an increase in project capacity. The investment is for 26% of equity in Torrent Urja, a captive hybrid (solar and wind) power project vehicle in Gujarat, and is paid in cash for 1,18,79,010 Class A equity shares of Rs. 10 each. Torrent Urja is an associate of the company and a step-down subsidiary of its holding company; the company states the transaction is at arm's length. The indicative completion period is 18 to 21 months; no governmental or regulatory approvals are stated as required. Torrent Urja has nil turnover as of 31 March 2026, was incorporated on 06 August 2024, and has not yet commenced business. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Aug 2026 | transcript | Torrent Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryTorrent Pharmaceuticals filed a letter dated 04 August 2026 under Regulation 30(6) of the SEBI LODR Regulations, 2015, informing exchanges that the transcript of its conference call with analysts and investors on results for the quarter ended 30 June 2026 has been placed on the company website. The transcript link provided is https://torrentpharma.com/pdf/investors/Q1-FY26-27_Earnings-Call-Transcript.pdf. The letter refers back to the company's earlier letter dated 17 July 2026 about the same call. The filing itself does not contain the call content, so management's remarks and tone cannot be taken from these pages. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jul 2026 | board outcome Acquisition, Management change, Results | Unaudited Financial Results for quarter ended 30-Jun-26AI summaryBoard of Torrent Pharmaceuticals approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, with limited review report; board meeting ran 2:00 pm to 4:40 pm. Filing encloses a press release on the financial results (Annexure B); the figures themselves are not in the pages provided. Auditor BSR & Co. LLP's limited review draws attention to the amalgamation of J. B. Chemicals & Pharmaceuticals Ltd (JBCPL) with the company, approved by NCLT on 6 July 2026 with appointed date 21 January 2026; comparative figures for quarter and year ended 31 March 2026 are restated, and the auditor's conclusion is not modified on this matter. Independent Director Ameera Shah (DIN: 00208095) completes her term on 1 August 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 May 2026 | transcript | Torrent Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryTorrent Pharmaceuticals filed a letter on 27 May 2026 giving the transcript of its conference call with analysts and investors on audited results for the quarter and year ended 31 March 2026. The transcript has been placed on the company website (Q4-FY25-26 Earnings Call Transcript PDF). The filing is made under Regulation 30(6) of SEBI (LODR) Regulations, 2015, in continuation of letters dated 12 May 2026 and 16 May 2026. The pages provided do not include the call content, so management's remarks on business performance and outlook are not stated here. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 22 May 2026 | board outcome Capex, Dividend / buy-back, Results | Torrent Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 22, 2026.AI summaryBoard of Torrent Pharmaceuticals approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, with audit reports carrying unmodified opinions; a press release on results is annexed. Board recommended a final dividend of ₹9 per equity share (180%) of ₹5 each, payable on or around 25 June 2026, subject to shareholder approval; record date fixed as 29 May 2026. An interim dividend of ₹29 per share (580%) was paid earlier in the last quarter. Board recommended that members approve issuance of equity shares, convertible bonds or debentures through QIP or other modes for up to ₹5,000 crores at the upcoming AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 22 May 2026 | presentation Results | Torrent Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryTorrent Pharmaceuticals filed the investor presentation for analysts on its audited financial results for the quarter and year ended 31 March 2026. Q4 FY26 total revenue was Rs 4,197 crore, up 43% from Rs 2,959 crore in Q4 FY25. Q4 FY26 India revenue was Rs 2,215 crore (up 43%), Brazil Rs 798 crore (up 68%), and United States Rs 396 crore (up 31%). FY26 total revenue was Rs 13,980 crore, up 21% from Rs 11,516 crore in FY25. FY26 India revenue was Rs 7,645 crore (up 20%), Brazil Rs 2,361 crore (up 32%), and United States Rs 1,363 crore (up 24%). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 22 May 2026 | dividend Capex, Dividend / buy-back, Results | Torrent Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 22, 2026, declared Select Dividend of Rs. 9 per equity share.AI summaryBoard approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, with unmodified audit opinions; a press release on results is enclosed. Board recommended a final dividend of ₹9 per equity share (180%) on a face value of ₹5, payable subject to shareholder approval on or around 25 June 2026; record date fixed as Friday, 29 May 2026. An interim dividend of ₹29 per equity share (580%) was paid in the last quarter. Board recommended members obtain enabling approval at the upcoming AGM for issuance of equity shares, convertible bonds or debentures through QIP or other modes up to ₹5,000 crores. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 22 May 2026 | board outcome Capex, Dividend / buy-back, Results | Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryBoard of Torrent Pharmaceuticals approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, with auditor reports carrying unmodified opinions. Board recommended a final dividend of ₹9 per equity share (180%) of ₹5 each to members, with 29 May 2026 fixed as record date; an interim dividend of ₹29 per share (580%) was paid earlier in the year. Board recommended enabling approval for issue of equity shares and convertible bonds/debentures through QIP and other modes for up to ₹5,000 crores at the upcoming AGM. A press release on the financial results was enclosed with the filing. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 Feb 2026 | transcript | Torrent Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryTorrent Pharmaceuticals filed a letter under Regulation 30(6) of the SEBI LODR Regulations, dated 20 February 2026, giving notice that the transcript of its analyst/investor conference call on results for the quarter and nine months ended 31 December 2025 has been posted on the company website. The filing itself contains no financial figures, and the transcript's content is not included in the pages provided. The transcript is available at torrentpharma.com/pdf/investors/Q3-FY25-26_Earnings-Call-Transcript.pdf. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | presentation Results | Torrent Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryTorrent Pharmaceuticals filed the investor/analyst presentation on its unaudited consolidated financial results for the quarter and nine months ended 31 December 2025. Q3 FY26 total revenues were Rs 3,303 crore, up 18% from Rs 2,809 crore in Q3 FY25; India Rs 1,798 crore (up 14%), United States Rs 321 crore (up 19%), Germany Rs 304 crore (up 8%), Brazil Rs 371 crore (up 27%), Others Rs 509 crore (up 32%). Nine-month (YTD Dec 25) total revenues were Rs 9,783 crore, up 14% from Rs 8,557 crore; India Rs 5,430 crore (up 12%), United States Rs 967 crore (up 21%), Germany Rs 916 crore (up 7%), Brazil Rs 907 crore (up 21%), Others Rs 1,563 crore (up 20%). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | dividend Dividend / buy-back, Results | Torrent Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on February 13, 2026, declared Interim Dividend of Rs. 29 per equity share.AI summaryTorrent Pharmaceuticals Limited filed the outcome of its board meeting held on 13 February 2026, with audited standalone and unaudited consolidated financial results for the quarter and nine months ended 31 December 2025, enclosed as Annexure A. The board approved an interim dividend of ₹29 per equity share of ₹5 fully paid up, shown as 580%. The dividend is expected to be paid or dispatched on or around 6 March 2026. A press release on the financial results is enclosed as Annexure B, but the figures for revenue and profit are not in the pages provided. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | board outcome Dividend / buy-back, Results | Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryTorrent Pharmaceuticals Limited's board approved audited standalone and unaudited consolidated financial results for the quarter and nine months ended 31 December 2025, with the auditor's report enclosed. The board approved an interim dividend of ₹29 per equity share (580%) on a face value of ₹5 per share, expected to be paid or dispatched on or around 6 March 2026. A press release on the financial results is enclosed with the filing; the consolidated results extract will be published as required under Regulation 47. The board meeting ran from 2:00 pm to 4:30 pm on 13 February 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | dividend Dividend / buy-back, Results | Torrent Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on February 13, 2026, declared Interim Dividend of 29 per equity share.AI summaryTorrent Pharmaceuticals Limited filed the outcome of its board meeting held on 13 February 2026, including audited standalone and unaudited consolidated financial results for the quarter and nine months ended 31 December 2025. The board approved an interim dividend of ₹29 per equity share (580%) on a face value of ₹5 per share. The dividend is expected to be paid or dispatched on or around 6 March 2026. A press release on the financial results is enclosed as Annexure-B; the pages provided do not include its figures. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Jan 2026 | credit rating Rating | Torrent Pharmaceuticals Limited has informed the Exchange about Credit RatingAI summaryTorrent Pharmaceuticals Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, dated 05 January 2026, about a credit rating action by ICRA Limited. ICRA reaffirmed the long-term rating of the company's banking facilities and Non-Convertible Debentures (NCDs) at [ICRA] AA+ (Stable). ICRA reaffirmed the rating of the existing amount and assigned a rating to the enhanced amount of the commercial paper programme at [ICRA] A1+. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Jan 2026 | board outcome Acquisition, Capex | Torrent Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on January 05, 2026.AI summaryTorrent Pharmaceuticals' Securities Transfer and Stakeholders Relationship Committee approved, at a meeting held on 5 January 2026 (10:00 am to 10:45 am), the issuance of secured, rated, listed, redeemable non-convertible debentures aggregating up to ₹12,500 crore in one or more tranches on a private placement basis. Up to 12,50,000 NCDs of face value ₹1,00,000 each are proposed, to be listed on the Wholesale Debt Market segment of the National Stock Exchange of India Limited. Coupon, allotment date and maturity date are to be determined at the time of issuance; coupon is to be paid annually. The security offered is a first-ranking exclusive charge over the designated proceeds account and specified trademarks, giving a minimum security cover of 1.1x. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 Jan 2026 | credit rating Rating | Torrent Pharmaceuticals Limited has informed the Exchange about Credit RatingAI summaryTorrent Pharmaceuticals Limited filed intimation under Regulation 30 of SEBI LODR regarding a credit rating from India Ratings and Research Private Limited. India Ratings affirmed the rating of the Company's existing banking facilities, issuer rating and Non-Convertible Debentures (NCDs) at IND AA+(Stable). India Ratings assigned a rating of IND A1+ to the Company's proposed Commercial Paper. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Nov 2025 | transcript | Torrent Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryTorrent Pharmaceuticals filed a letter dated 13 November 2025 under Regulation 30(6) of SEBI LODR, giving notice that the transcript of its earnings conference call with analysts and investors on results for the quarter and half year ended 30 September 2025 has been placed on the company's website. The letter gives the link to the transcript PDF and is signed by Company Secretary Chintan M. Trivedi. The filing itself contains no financial figures or management commentary beyond the cover note. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2025 | presentation Results | Torrent Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryTorrent Pharmaceuticals filed the investor/analyst presentation on its unaudited consolidated results for the quarter and half year ended 30 September 2025 (filed 7 November 2025). Q2 FY26 total revenue was Rs 3,302 crore, up 14% from Rs 2,889 crore in Q2 FY25. Q2 FY26 revenue by segment (Rs crore, Q2 FY25 to Q2 FY26): India 1,632 to 1,820 (up 12%); United States 268 to 337 (up 26%); Germany 288 to 303 (up 5%); Brazil 263 to 318 (up 21%); Others 438 to 524 (up 20%). H1 FY26 total revenue was Rs 6,480 crore, up 13% from Rs 5,748 crore in H1 FY25. H1 FY26 revenue by segment (Rs crore, H1 FY25 to H1 FY26): India 3,267 to 3,631 (up 11%); United States 527 to 646 (up 23%); Germany 572 to 612 (up 7%); Brazil 459 to 536 (up 17%); Others 923 to 1,055 (up 14%). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2025 | board outcome Results | Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations )AI summaryTorrent Pharmaceuticals' board approved the audited standalone financial results and unaudited consolidated financial results for the quarter and half year ended 30 September 2025, on 7 November 2025. The auditor BSR & Co. LLP issued an unmodified audit report on the standalone results for the quarter and the year-to-date period from 1 April 2025 to 30 September 2025. The company will publish an extract of the unaudited consolidated results under Regulation 47; full results are available on the company website. A press release on the financial results was enclosed with the filing. The board meeting ran from 2:10 pm to 5:30 pm. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Oct 2025 | credit rating Rating | Torrent Pharmaceuticals Limited has informed the Exchange about Credit RatingAI summaryTorrent Pharmaceuticals Limited filed an intimation of credit ratings from ICRA Limited under Regulation 30 of SEBI LODR, dated 7 October 2025. ICRA reaffirmed the long-term rating of the banking facilities and existing NCDs at [ICRA] AA+ (Stable). ICRA assigned a rating of [ICRA] AA+ (Stable) to the proposed NCDs of the company. ICRA reaffirmed the rating of the commercial paper programme at [ICRA] A1+. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Oct 2025 | credit rating Rating | Torrent Pharmaceuticals Limited has informed the Exchange about Credit Rating- NewAI summaryTorrent Pharmaceuticals Limited intimated under Regulation 30 of SEBI LODR that India Ratings and Research Private Limited has affirmed the credit rating of the Company's existing banking facilities, issuer rating and Non-Convertible Debentures (NCDs). India Ratings and Research also assigned a credit rating to the Company's proposed NCDs. The ratings were affirmed or assigned at IND AA+ (Stable). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Sep 2025 | acquisition Acquisition, Capex | Torrent Pharmaceuticals Limited has informed the Exchange about AcquisitionAI summaryTorrent Pharmaceuticals entered a Share Subscription and Shareholders' Agreement on 10 September 2025 to subscribe to 26% of the equity of Torrent Urja 27 Private Limited. Torrent Urja is a special purpose vehicle formed for a captive hybrid (solar + wind) power project in Gujarat; it had nil turnover as on 31 March 2025 and has not commenced business. The consideration is cash of INR 7,91,93,400 for 79,19,340 Class A equity shares of Rs. 10 each. Management said the investment is intended to enhance the share of renewable power sources in the company's operations and to meet the captive user requirement under Indian electricity laws. The indicative time period for completion is 18 to 20 months; the company described the deal as a related party transaction on an arm's length basis, as Torrent Urja is a step-down subsidiary of the holding company. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 31 Jul 2025 | transcript | Torrent Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryTorrent Pharmaceuticals filed the transcript of its Q1 FY2025-26 (quarter ended 30 June 2025) earnings conference call with analysts and investors, under Regulation 30(6) of the SEBI LODR Regulations. The transcript has been placed on the company's website at torrentpharma.com. The filing itself does not contain the call's content, so management's statements and figures are not reproduced in these pages. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jul 2025 | board outcome Dividend / buy-back, Results | Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryThe Board approved the audited standalone financial results and unaudited consolidated financial results for the quarter ended 30 June 2025, with auditor's report and limited review report enclosed, along with a press release on the results. The Board also approved the issuance of unsecured/secured redeemable non-convertible debentures/bonds by private placement within the company's borrowing limits. The Board meeting commenced at 02:00 pm and concluded at 03:40 pm on 28 July 2025. The pages provided do not state the revenue, profit or other figures from the results. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jul 2025 | presentation Results | Torrent Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryTorrent Pharmaceuticals filed the investor presentation for analyst meeting on unaudited consolidated financial results for the quarter ended 30 June 2025. Total revenues for Q1 FY26 were Rs 3,178 crore, up 11% from Rs 2,859 crore in Q1 FY25. India revenues rose 19% to Rs 308 crore from Rs 259 crore... Revenue by region in Q1 FY26 (Rs crore): India 1,811 (up 11% from 1,635); United States 308 (up 9% from 284); Germany 218 (up 11% from 196); Brazil 533 (up 10% from 485). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jul 2025 | board outcome Dividend / buy-back, Results | Torrent Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on July 28, 2025. - Financial ResultsAI summaryBoard approved audited standalone financial results and unaudited consolidated financial results for the quarter ended 30 June 2025, with limited review report; the filing encloses these results and a press release on the results. Board also approved issuance of unsecured/secured redeemable non-convertible debentures/bonds by private placement within the company's borrowing limits. The pages provided do not include the financial figures (revenue, profit, dividend) or management commentary. Board meeting commenced at 2:00 pm and concluded at 3:40 pm on 28 July 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jun 2025 | presentation Acquisition, Legal | Torrent Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryTorrent Pharmaceuticals filed an investor presentation on its acquisition of a controlling stake in JB Chemicals & Pharmaceuticals. The SPA covers a 46.39% equity stake (fully diluted) at INR 11,917 crores (INR 1,600 per share), which triggers a mandatory open offer for up to 26% at INR 1,639.18 per share. Torrent also intends to acquire up to 2.80% of equity shares from JB Pharma employees, and plans to merge with JB Pharma with Torrent as the surviving listed entity. JB Pharma shareholders would receive 51 Torrent equity shares for every 100 JB Pharma shares under the swap ratio. Approvals required include CCI, stock exchanges and SEBI; indicative implementation timeline is 15-18 months. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jun 2025 | board outcome Acquisition, Capex, Legal | Torrent Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 29, 2025.AI summaryTorrent Pharmaceuticals' board approved, on 29 June 2025, the acquisition of 7,44,81,519 equity shares (46.39% fully diluted) of J.B. Chemicals & Pharmaceuticals from promoter Tau Investment Holdings at INR 1,600 per share, for a total consideration of about INR 11,917 crore in cash. The board also approved a potential acquisition of up to 44,99,782 shares (up to 2.80%) from employees of the target on exercise of vested ESOPs at a price not exceeding INR 1,600 per share. The board approved an open offer for up to 4,17,45,264 shares (26.00% of expanded share capital) at INR 1,639.18 per share, and a scheme of amalgamation of J.B. Chemicals with the company under Sections 230 to 232 of the Companies Act, 2013. A share purchase agreement dated 29 June 2025 was executed, and a merger implementation agreement was approved for execution. The transaction is subject to shareholder approval, Competition Commission of India approval, and other statutory and regulatory approvals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 May 2025 | transcript | Torrent Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryTorrent Pharmaceuticals filed a letter with BSE and NSE on 23 May 2025 giving notice of the transcript of its conference call with analysts and investors on audited financial results for the quarter and year ended 31 March 2025. The transcript has been placed on the company's website at https://www.torrentpharma.com/assets/TorrentPharma-Earnings-May20-2025.pdf. The filing was made under Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and follows the company's letter dated 13 May 2025. The pages provided do not include the transcript content or any management commentary. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 May 2025 | board outcome Capex, Dividend / buy-back, Management change, Results | Torrent Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 20, 2025. - Fund RaisingAI summaryBoard of Torrent Pharmaceuticals approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, with unmodified audit reports, and a press release on the results was attached. Board recommended a final dividend of ₹6 per equity share (120%) of face value ₹5, with record date 20 June 2025 and payment on or around 4 August 2025; an interim dividend of ₹26 per share (520%) was paid earlier in the last quarter. Board recommended seeking shareholder enabling approval at the upcoming AGM for issuance of equity shares and convertible bonds/debentures through QIP and other modes up to ₹5,000 crores. Board recommended appointing Aman Mehta (DIN 08174906), current Whole-time Director, as Managing Director and Whole-time KMP for 5 years with effect from 1 August 2025, subject to shareholder approval at the AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 May 2025 | presentation Results | Torrent Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryTorrent Pharmaceuticals filed the investor presentation for analysts on its audited financial results for the quarter and year ended 31 March 2025. Q4 FY25 total revenue was Rs 2,959 crore, up 8% from Rs 2,745 crore in Q4 FY24; India revenue rose 12% to Rs 1,545 crore and United States revenue rose 15% to Rs 302 crore. FY25 total revenue was Rs 11,516 crore, up 7% from Rs 10,728 crore in FY24; India revenue rose 13% to Rs 6,393 crore. FY25 United States revenue was Rs 1,100 crore, up 2% from Rs 1,078 crore, while Brazil revenue fell 2% to Rs 1,100 crore. The extract contains only revenue tables and no management commentary on outlook. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 May 2025 | dividend Capex, Dividend / buy-back, Management change, Results | Torrent Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 20, 2025, declared Select Dividend of Rs. 6 per equity share.AI summaryTorrent Pharmaceuticals' board, meeting held on 20 May 2025, approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, with unmodified audit opinions. The board recommended a final dividend of ₹6 per equity share (120%) on shares of ₹5 each, to be paid on or around 4 August 2025; an interim dividend of ₹26 (520%) per share was paid earlier in the year. The record date for the final dividend is Friday, 20 June 2025. The board recommended seeking shareholder approval at the upcoming AGM for issuance of equity shares and convertible instruments through QIP or other modes up to ₹5,000 crores. The board recommended appointing Whole-time Director Aman Mehta as Managing Director and Whole-time KMP for 5 years from 1 August 2025, subject to shareholder approval at the AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 20 May 2025 | board outcome Acquisition, Dividend / buy-back, Management change, Results | Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.AI summaryBoard of Torrent Pharmaceuticals approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, with unmodified audit reports; a press release on the results is attached. Board recommended a final dividend of ₹6 per equity share (120%) of ₹5 each, record date 20 June 2025, payable on or around 4 August 2025; an interim dividend of ₹26 per share (520%) was paid earlier in the last quarter. Board recommended enabling approval for issuance of equity shares and convertible bonds/debentures through QIP and/or other modes up to ₹5,000 crores at the upcoming AGM. Board recommended appointment of Aman Mehta (DIN 08174906), currently Whole-time Director, as Managing Director and Whole-time KMP for 5 years w.e.f. 1 August 2025, subject to shareholder approval at the AGM. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 Mar 2025 | credit rating Rating | Torrent Pharmaceuticals Limited has informed the Exchange about Credit RatingAI summaryTorrent Pharmaceuticals Limited intimated under Regulation 30 of SEBI LODR that ICRA Limited reaffirmed the long-term credit rating of its banking facilities and non-convertible debentures at [ICRA] AA+ (Stable). ICRA Limited reaffirmed the rating for the existing amount of the commercial paper programme at [ICRA] A1+. ICRA Limited assigned the [ICRA] A1+ rating to the enhanced amount of the commercial paper programme. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 31 Jan 2025 | transcript | Torrent Pharmaceuticals Limited has informed the Exchange about TranscriptAI summaryTorrent Pharmaceuticals filed a letter dated 31 January 2025 giving the transcript of its conference call with analysts and investors on results for the quarter and nine months ended 31 December 2024. The transcript has been placed on the company's website under Regulation 30(6) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The letter refers back to an earlier letter dated 15 January 2025. The pages provided do not include the management remarks, so no management commentary or tone can be drawn from this filing. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Jan 2025 | results Results | Integtated Filling - FinancialAI summaryTorrent Pharmaceuticals filed its integrated financial filing for the quarter and nine months ended 31 December 2024, under SEBI circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185. The filing includes the financial results (Annexure-I), with standalone results audited by BSR & Co. LLP, which gave an unmodified opinion. The company states there is no default on loans and debt securities outstanding as of 31 December 2024. The pages provided do not include the actual revenue, profit or other figures from Annexure-I. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Jan 2025 | presentation Results | Torrent Pharmaceuticals Limited has informed the Exchange about Investor PresentationAI summaryTorrent Pharmaceuticals filed the investor presentation for analysts on its unaudited consolidated financial results for the quarter and nine months ended 31 December 2024. Q3 FY25 total revenue was Rs 2,809 crore versus Rs 2,732 crore in Q3 FY24, up 3%. Q3 FY25 India revenue was Rs 1,581 crore (up 12%) and Brazil revenue was Rs 384 crore (down 16%). 9M FY25 total revenue was Rs 8,557 crore versus Rs 7,983 crore in 9M FY24, up 7%. 9M FY25 India revenue was Rs 4,848 crore (up 13%) and Brazil revenue was Rs 1,308 crore (down 2%). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.